Clinical & Translational Oncology最新文献

{"title":"Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study.","authors":"Shalini Chaturvedi, Anke Weispfenning, Tine Descamps, Sara Bellinvia, David Bauer, Rong Du, Teresa Lunt, Lidia Mongay Soler, Barrett H Childs, Pier Luigi Zinzani","doi":"10.1007/s12094-025-03869-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03869-2","url":null,"abstract":"<p><strong>Purpose: </strong>There has been increased difficulty in developing safe and effective treatment using PI3K inhibitors in heme malignancies, despite the role of PI3K/AKT being well defined in this population. This study was an attempt to conduct exploratory biomarker analysis retrospectively from the phase III CHRONOS-3 trial with the aim to identify a sub-set of patients that could benefit from treatment.</p><p><strong>Patients and methods: </strong>Patients with CD20-positive indolent B-cell lymphoma were randomized 2:1 to receive intravenous copanlisib plus rituximab (C + R) or placebo plus rituximab (P + R). Biomarker analyses were performed to examine potential associations between treatment outcome and phosphatase and tensin homolog (PTEN) protein expression, EZH2 and BCL2 mutation status via next-generation sequencing, and plasma cytokine levels.</p><p><strong>Results: </strong>PTEN presence was associated with significant improvements in progression-free survival (PFS) for C + R over P + R in patients with iNHL (P = 0.001) and FL (P = 0.012). Both the mutant and wild-type EZH2 FL patients had equal PFS benefits when treated with copanlisib. A significant improvement in PFS was observed for patients with mutant versus wild-type BCL2 FL in the C + R arm (P = 0.002). Overall survival (OS) was significantly improved for patients with iNHL and low or undetectable versus high baseline IL-2 levels in the C + R arm (P < 0.0001, unadjusted).</p><p><strong>Conclusions: </strong>PTEN presence, BCL2 mutations, and low or undetectable baseline IL-2 levels were associated with improved patient survival following treatment with C + R, supporting a potential role for these biomarkers in guiding treatment selection for patients with indolent non-Hodgkin lymphoma.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical metric of tumor mutational burden depicts colorectal cancer patients at the extremes.","authors":"Ming Zheng","doi":"10.1007/s12094-025-03873-6","DOIUrl":"https://doi.org/10.1007/s12094-025-03873-6","url":null,"abstract":"<p><strong>Purpose: </strong>Rare cases of colorectal cancer patients with exceptionally good or poor prognosis often remain overlooked, limiting insights into prognostic factors and underlying mechanisms.</p><p><strong>Methods: </strong>This study developed an analytical framework to investigate cancer patients at the extremes using tumor mutational burden (TMB). By analyzing data from 1277 colorectal cancer patients who did not receive immunotherapy, this analysis assessed how patient survival varies with a broad range of TMB levels.</p><p><strong>Results: </strong>Among patients with TMB ≤ 10 mutations per megabase (mut/Mb), increasing TMB was associated with worse survival outcomes. In contrast, patients with TMB > 10 mut/Mb showed  increasingly improved survival. Notably, a small subgroup (3.83%) with TMB > 60 mut/Mb had significantly better survival outcomes.</p><p><strong>Conclusions: </strong>These findings highlight TMB's dual role in colorectal cancer progression. This study suggests that atypical patients can coexist within the same \"disease continuum\" with typical patients, under the universal context unified by a shared cancer hallmark. TMB provides a useful biomarker for identifying these extremes, offering a clinical metric to better predict patient outcomes and personalize treatment strategies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dendritic cell immunotherapy has its antitumor action improved by the LPS in the maturation process.","authors":"Angela Maria Moed Lopes, Jéssica Ferreira Vieira, Saulo Fernando Moreira da Silva, Eddie Fernando Candido Murta, Márcia Antoniazi Michelin","doi":"10.1007/s12094-025-03858-5","DOIUrl":"https://doi.org/10.1007/s12094-025-03858-5","url":null,"abstract":"<p><p>Immunotherapy with dendritic cells (DCs) in cancer patients aims to activate the immune response to eliminate neoplastic cells. The present study aimed to investigate lipopolysaccharide (LPS)-stimulated bone marrow-derived dendritic cells in investigating antitumor immune response in experimental breast cancer. For this, we submitted bone marrow pluripotent cells of Balb/c mice differentiated by GM-CSF and IL-4 to maturation with TNF-α and tumor lysate (DCs protocol) or with TNF-α, LPS, and tumor lysate (LPS/DCs protocol). Both immunotherapies were tested in 4T1 breast cancer to evaluate their impact on splenic and tumor microenvironment. We observed that DCs and LPS/DCs reduce the tumor growth rate (p < 0.0001). Besides, the LPS/DCs vaccine shows higher splenic and intratumoral T helper lymphocytes (p < 0.001). Both vaccines increased the production of IFN-γ in the tumor microenvironment (p < 0.0001). The LPS/DCs induced lower Treg lymphocytes and macrophages in the tumor microenvironment (p < 0.0001). The results allow us to conclude that bone marrow-derived dendritic cells stimulated with LPS have been shown to reduce tumor growth rate efficiently and could be better immunotherapy in breast cancer by reducing immunosuppressive cells and increasing antitumoral immune cells in the tumor microenvironment.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population-based study of incidence trends of head and neck epithelial cancers in northeastern Spain, 1994-2018.","authors":"Jordi Rubió-Casadevall, Jan Trallero, Carla Calvo, Montse Puigdemont, Marià Carulla, Arantza Sanvisens, Alberto Ameijide, Anna Vidal, Clàudia Pla, Jordi Marruecos, Rafael Marcos-Gragera, Jaume Galceran","doi":"10.1007/s12094-025-03855-8","DOIUrl":"https://doi.org/10.1007/s12094-025-03855-8","url":null,"abstract":"<p><strong>Background: </strong>Head and neck cancer (HNC) is the seventh most common cancer worldwide. Incidence rates of these tumors vary between countries and change over time depending on the prevalence of risk factors such as tobacco and alcohol consumption, betel nut chewing habits or human papillomavirus infection. This makes it necessary to periodically study HNC incidence trends in each geographic area.</p><p><strong>Methods: </strong>To determine trends in the incidence of HNC, all cancer cases diagnosed in Girona and Tarragona (northeastern Spain) between 1994 and 2018, except mesenchymal and hematological neoplasms, were included. Crude and standardized incidence rates and the annual percentage change (APC) were calculated.</p><p><strong>Results: </strong>We identify 7,966 cases of HNC, 83.7% in men. A significant decrease in incidence, with an APC of  - 1.83, was observed in all HNC as a whole and in cancers of the lip (APC =  - 5.34), salivary glands (APC =  - 2.22), nasopharynx (APC =  - 2.01), hypopharynx (APC =  - 3.15), and larynx (APC =  - 1.97). In men, a significant decline in incidence was observed in overall HNC and in cancers of the lip, oral cavity, salivary glands, nasopharynx, hypopharynx, and larynx. In women, a significant increase was identified in overall HNC and in cancers of oral cavity, oropharynx, hypopharynx, and larynx.</p><p><strong>Conclusion: </strong>A decline in the overall incidence of HNC has been observed in this area of southern Europe, mainly based on a decrease in men of cancers of the lip, oral cavity, salivary glands, nasopharynx, hypopharynx, and larynx.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a novel hypermethylation marker, ZSCAN18, and construction of a diagnostic model in cervical cancer.","authors":"Jinhao Yang, Shuang Chen, Yuqing Liu, Ping Wang, Jing Zhao, Jianying Yi, Jin Wei, Rong Wang","doi":"10.1007/s12094-025-03864-7","DOIUrl":"https://doi.org/10.1007/s12094-025-03864-7","url":null,"abstract":"<p><strong>Purpose: </strong>Cervical cancer (CC), a common female malignancy, has been linked to alterations in DNA methylation. This study employed an integrated \"dry-wet lab\" strategy combining bioinformatics, machine learning, and experimental validation to identify novel methylation biomarkers for CC.</p><p><strong>Methods: </strong>Methylome and transcriptome data from the TCGA and GEO cohorts (n=349 discovery, n=414 validation) were analyzed to identify differentially methylated CpGs. The top candidates were validated by pyrosequencing, methylation-specific PCR, and quantitative assays. Diagnostic models were developed, and functional studies were performed for the target markers.</p><p><strong>Results: </strong>Eighteen differentially methylated CpGs were identified, with five top candidates (three in the ZSCAN18 promoter) showing diagnostic potential. ZSCAN18 promoter methylation levels and positivity rates were significantly greater in CC tissues than in normal tissues (p<0.05), reaching 77.8% (21/27) in ThinPrep cytology test (TCT) samples. The ridge regression diagnostic model achieved an AUC of 0.9421 in the validation cohort. Similarly, ZSCAN18 overexpression suppressed CC cell proliferation (p<0.05).</p><p><strong>Conclusions: </strong>This study established a rapid, effective and systematic systemic research strategy to screen novel methylation markers for CC. ZSCAN18 promoter methylation correlates with cervical lesion severity, and the diagnostic model enhances the diagnostic ability. These findings highlight the dual role of ZSCAN18 as a diagnostic marker and potential therapeutic target.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.","authors":"Mohammad Taghizadeh-Teymorloei, Vahid Jafarlou, Somaieh Matin, Mortaza Raeisi, Yousef Roosta, Sima Mansouri-Derakhshani, Abbas Ali Hosseinpour Feizi, Abbas Karimi","doi":"10.1007/s12094-025-03863-8","DOIUrl":"https://doi.org/10.1007/s12094-025-03863-8","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) remains a significant global health challenge, characterized by high morbidity and mortality rates. This study explores the potential of Alu-based cell-free DNA (cfDNA) and specific PIWI-interacting RNAs (piRNAs) as innovative biomarkers for monitoring treatment responses in CRC patients.</p><p><strong>Methods: </strong>We analyzed plasma samples from 70 CRC patients, equally divided between those undergoing chemotherapy and surgical interventions.</p><p><strong>Results: </strong>Our findings reveal that certain piRNAs, particularly piRNA-823, piRNA-54265, and piRNA-1245, exhibit significant prognostic value, with notable expression changes observed in the chemotherapy group compared to the surgery group. Furthermore, the levels of ALU-based cfDNA fragments showed a marked decrease post-chemotherapy, suggesting their utility in assessing therapeutic efficacy.</p><p><strong>Conclusions: </strong>This research underscores the importance of integrating these molecular tools particularly piRNA-823 and ALU-based cfDNA into clinical practice, potentially enhancing the management strategies for CRC patients and improving their outcomes.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse large B-cell lymphoma: examining evolving patterns in mortality, incidence, and demographics.","authors":"Silpa Choday, Eric Tran, Miguel Gonzalez","doi":"10.1007/s12094-025-03859-4","DOIUrl":"https://doi.org/10.1007/s12094-025-03859-4","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and heterogeneity. This study analyzes recent trends in DLBCL including trends in hospitalization, inpatient mortality, and costs.</p><p><strong>Methods: </strong>Using the Nationwide Inpatient Sample (NIS) database from 2016 until 2020, a retrospective cohort study was performed to identify DLBCL hospitalization, discharges, and investigate outcomes. Trends were adjusted for age, sex, race, insurance type, mean household income, and hospital characteristics. Multivariable logistic regression has been used to analyze the data.</p><p><strong>Results: </strong>A total of 103,588,729 records were analyzed, identifying 47,425 cases with a diagnosis of DLBCL. From 2016 to 2020, hospitalizations have increased from 14,980 to 16,565. The mean age at diagnosis was 65 (P < 0.001). Males were slightly more affected than females (57.3 vs 42.6), with an increasing trend in males from 53.7% to 62.3% (P = 0.03). The highest prevalence was observed in the White population, followed by Hispanics and African Americans. Notably, the prevalence among Hispanics increased from 10 to 12%, while there is a decreasing trend in other demographics (P = 0.05). Medicare was the most common insurance, with increasing trends, followed by Medicaid and private insurance (P = 0.6). Inpatient mortality increased from 6.1 to 7.1 (2016 to 2018) and decreased to 6.1% (2018 to 2020) (P < 0.001). The mean length of the stay remained stable at 11.8 days. However, hospital charges increased from $176,131 to $212,324. Comorbidities such as obesity, hypertension, other associated lymphomas, peripheral vascular diseases, and diabetes showed an increasing trend (P < 0.05). Discharges to home and skilled nursing facility (SNF) decreased, while there was an increase in discharges to home with home health (HH) care and short-term care (P < 0.001).</p><p><strong>Conclusion: </strong>Risk factors for DLBCL include white male sex, with the mean age of 65 years. The incidence among the Hispanic population has been increasing over the years. There are disparities in incidence and survival among different ethnic/demographic groups that need to be addressed by identifying targeted interventions and equitable healthcare access.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.","authors":"Ignacio Peláez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, Emilio Esteban-González, Enrique Gallardo, Carlos Álvarez-Fernández, Pablo Álvarez Rodríguez, Urbano Anido-Herranz, Cristina Azpitarte Raposeiras, Ángel Maximino Castro-Iglesias, Ovidio Fernández Calvo, Natalia Fernández Núñez, Alicia Folgar-Torres, Carme García Lorenzo, Aránzazu González-Del-Alba, María José Méndez-Vidal, Aurea Molina Díaz, Ignacio Rodríguez Gómez, Sergio Vázquez-Estévez","doi":"10.1007/s12094-025-03850-z","DOIUrl":"10.1007/s12094-025-03850-z","url":null,"abstract":"<p><p>Prostate, bladder and kidney neoplasms are among the most prevalent genitourinary (GU) cancers worldwide. Significant therapeutic advancements in recent years have substantially improved patient outcomes. In response to this rapid progress, the Santiago de Compostela Health Research Institute (IDIS) has organized the annual 'Cambados Consensus Forum on Genitourinary Tumors' (Pontevedra, Spain) since 2018. This 2-day multidisciplinary meeting gathers Spanish medical oncologists, radiation oncologists, urologists, and hospital pharmacists to present and discuss the latest evidence in the field, merging from international congresses or journal publications. This review provides an overview of the most recent evidence regarding therapeutic advances in prostate cancer, renal cell carcinoma, and bladder cancer presented at the 2024 meeting (October), with a special focus on practice-changing innovations.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy.","authors":"Yuanliang Zhou, Jingchao Li, Yankang Li, Guangchuan Deng, Qi Wang, Hongyue Qin, Jianbin Li, Zhenxiang Li","doi":"10.1007/s12094-025-03867-4","DOIUrl":"https://doi.org/10.1007/s12094-025-03867-4","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burnout levels among radiation oncology residents in Spain: a cross-sectional survey.","authors":"Elías Gomis Sellés, María Mingarro de León, Ángel Montero, Meritxell Arenas","doi":"10.1007/s12094-025-03862-9","DOIUrl":"https://doi.org/10.1007/s12094-025-03862-9","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the prevalence and characteristics of burnout among Radiation Oncology residents in Spain, focusing on its associated risk factors and implications for residency training.</p><p><strong>Materials and methods: </strong>A cross-sectional online survey was conducted from June to September 2024, using the Maslach Burnout Inventory (MBI) to evaluate emotional exhaustion, depersonalization, and self-fulfillment. Residents from various Spanish regions completed an anonymous questionnaire covering workload and burnout.</p><p><strong>Results: </strong>Fifty residents, predominantly in their third (38%) and fourth (42%) years of training, participated. High emotional exhaustion was reported by 58%, while 54% exhibited elevated depersonalization. Self-fulfillment scores were low in 32%. Overall, 70% experienced at least one burnout symptom, with 12% meeting criteria for full-burnout syndrome. An inverse correlation between self-fulfillment and emotional exhaustion was observed (p = 0.007). Trends suggested higher burnout risk in senior residents (R3-R4) compared to juniors (R1-R2), though these differences were not statistically significant (OR = 1.682; p = 0.086).</p><p><strong>Conclusion: </strong>The findings reveal a high prevalence of at least one burnout symptom among Radiation Oncology residents in Spain, with emotional exhaustion and depersonalization notably elevated. However, full-burnout syndrome is not prevalent. These findings underscore the need for reforms in residency training programs, emphasizing workload management, well-being initiatives, and support for scientific and professional development.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}